

## DISCHARGE

---

### FIRST AMENDMENT TO AGREEMENT BETWEEN MASARYKOVA UNIVERZITA and ECRIN-ERIC

This first amendment (the " First Amendment") to the AGREEMENT FOR THE PERFORMANCE OF THE TRIAL DISCHARGE (the "Agreement"), the Project ID: NCT0240022, is made by and between:

**European Clinical Research Infrastructure Network (ECRIN-ERIC)**, registered under SIRET n°801 933 235 00021, established in 5-7 rue Watt, 75013 Paris, France, represented by Prof. Dr. Jacques Demotes, Director General of ECRIN ERIC

Hereinafter referred to as "**ECRIN**"

AND

**Masarykova univerzita**, whose registered office Žerotínovo náměstí 617/9, Brno 601 77, Czech ID number 00216224, VAT number: CZ00216224.

represented by:

Prof. MUDr. Martin Bareš, Ph.D., the Dean of the Faculty of Medicine, contact address: Kamenice 5, Brno-Bohunice, 625 00, Czech Republic

Hereinafter referred to as "**ECRIN PARTNER**"

Hereinafter individually or collectively referred to as the "Party" or the "Parties".

### WHEREAS

ECRIN PARTNER and ECRIN entered into an agreement (**Agreement\_DISCHARGE\_ECRIN\_Masaryk University, Czech Republic, Version 01\_03072017**) (the "Agreement") for the performance of Clinical trial entitled **DISCHARGE**.

The Clinical trial is the core part of the **DISCHARGE Project** of an European Consortium which receives funding from the European Union H2020 programme under Grant Agreement no. 603266.

The Agreement between the Parties will expire on **November 30th, 2018**, and the Parties want to extend the aforementioned Agreement for an additional term commencing upon the expiration of the original term and shall now expire on **January 31st, 2019** (Termination date).

In addition, due to the patient shift and increased monitoring activities, the Parties want to modify the aforementioned Agreement as follows:

1. The **Appendix 2: Price and payments (Agreement Version 01\_03072017)** of the agreement is modified and replaced by **Appendix 2: Price and payments (Agreement Version 02\_23)** as described below:

The following words shall be added at the end of Appendix 2 (**Agreement Version 01\_03072017**), after the Budget (price list) table:

**"Additional Monitoring visits (MV) might be requested but would depend on the Sponsor decision. Any additional MV will then need to be approved by ECRIN and the Sponsor and will be invoiced (same cost as the other visits, i.e. 704 EUR per one MV) after the confirmation receipt of monitoring report of the performed visit".**

All other terms and conditions of the Agreement shall remain in effect and unchanged.

ECRIN acknowledges that the ECRIN PARTNER is an obligated subject under the Czech act no. 340/2015 Coll. of the Czech Republic, on special conditions for the effectiveness of some contracts, the disclosure of these contracts and the Registry of contracts (Act on the Registry of contracts). Provisions of the Act on the Registry of contracts obligates public institutions (such as Masarykova univerzita) to transparently publish a copy of this amendment in a central repository of contracts (Registry of contracts) before the amendment enters into force.


The First Amendment is considered concluded as from the date of signature of the last Party to sign the amendment. The effective date is the date when a copy of this amendment has been published in the Registry of contracts.

**IN WITNESS WHEREOF**, the parties, acting through their duly authorized representatives, have executed two (2) copies of this Amendment to the Agreement

**1. For and on behalf of ECRIN PARTNER**  
LEGAL REPRESENTATIVE  
Prof. MUDr. Martin Bareš, Ph.D.  
Dean of the Faculty of Medicine

**2. For and on behalf of ECRIN**  
LEGAL REPRESENTATIVE:  
Prof. Dr. Jacques Demotes  
Director General of ECRIN ERIC

DATE: 27 -11- 2018 SIGNATURE:



DATE: 27 Nov 2018 SIGNATURE:

